登录新浪财经APP 搜索【信披】查看更多考评等级 关于公司参与国家组织集采药品协议期满品种接续采购拟中选的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 珠海润都制药股份有限公司（以下简称"公司"）参加了国家组织集采药品协议期满品种接续采购办公室 (以下简称"接续采购办公室")组织的国家组织集采药品协议期满品种接续采购的投标工作(以下简称"本 次接续采购")，根据接续采购办公室于2026年02月10日发布的《国家组织集采药品协议期满品种接续采 购拟中选结果公示》，公司部分药品拟中选本次接续采购，现将相关情况公告如下： 一、拟中选产品情况 ■■ 二、本次拟中选对公司的影响 本次接续采购品种为第1-8批国家组织集采协议期满的品种，各采购品种的约定采购量以医药机构填报 各企业采购品种需求量为基数，按照中选价格梯度确定带量比例，本次拟中选药品的采购周期自中选结 果实际执行日起至2028年12月31日。 在采购周期内，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采购量。若后续签订 采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形 ...

Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd. has participated in the national organized procurement of drugs and has announced that several of its products are proposed to be selected for the continuation of procurement after the expiration of the previous agreement [1][3]. Group 1: Proposed Selected Products - The company has a total of 12 products proposed for selection in this procurement process [3]. - The procurement cycle for the selected products will last until December 31, 2028, starting from the actual execution date of the selection results [2]. Group 2: Financial Impact - The projected sales revenue from the selected products is estimated to be 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [3]. - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [3]. - The selected products are expected to enhance the company's market share and brand influence as medical institutions will prioritize these products during the procurement cycle [3].

Core Viewpoint - Chengyi Pharmaceutical (603811) announced that four of its products have been selected for the national centralized procurement program, with a procurement period extending to December 31, 2028, covering nationwide regions [1] Group 1: Product Details - The four selected products include Glucosamine Hydrochloride Capsules, Torasemide Injection, Lidocaine Hydrochloride Injection, and L-Carnitine Injection, each targeting specific medical conditions such as osteoarthritis, heart failure, local anesthesia, and complications from chronic kidney disease [1] - Glucosamine Hydrochloride Capsules are indicated for the treatment and prevention of osteoarthritis, with selected specifications of 750mg in 120 capsules and 750mg in 60 capsules [1] - Torasemide Injection is aimed at patients with edema due to congestive heart failure and liver cirrhosis, with selected specifications of 2ml:10mg in 10 vials and 4ml:20mg in 5 vials [1] - Lidocaine Hydrochloride Injection serves as a local anesthetic and antiarrhythmic agent, with a selected specification of 5ml:0.1g in 5 vials [1] - L-Carnitine Injection is for patients with chronic kidney disease undergoing long-term dialysis, with selected specifications of 5ml:1g in 5 vials and 5ml:2g in 5 vials [1] Group 2: Revenue Contribution - Among the four products, Glucosamine Hydrochloride Capsules are the core product, contributing significantly to revenue, with projected sales of 334.89 million yuan in 2024, accounting for 46.88% of the company's total revenue for that year [2] - For the first three quarters of 2025, the revenue from Glucosamine Hydrochloride Capsules is expected to reach 345.37 million yuan, representing 57.85% of the company's revenue during that period [2] - The other three products have relatively smaller revenue contributions, with Torasemide Injection generating 6.55 million yuan in 2024 and 4.20 million yuan in the first three quarters of 2025, accounting for 0.92% and 0.70% of total revenue, respectively [2] - Lidocaine Hydrochloride Injection and L-Carnitine Injection have minimal revenue, with figures below 0.1% for the respective periods [2] Group 3: Procurement Process - The centralized procurement process involves a coalition of provinces and regions across the country, led by Jiangsu, Henan, and Guangdong provinces to conduct unified procurement [3] - During the procurement period, medical institutions will prioritize the use of the selected drugs and ensure the completion of the agreed procurement volume [3] - Any remaining procurement volume after calculating the volume-based ratio can be selected from other companies that meet the bidding criteria [3]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including Montmorillonite Powder, being proposed for selection in this procurement [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - During the procurement cycle, medical institutions will prioritize the use of the selected drugs, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has participated in the national organized procurement for drugs whose agreements have expired, with several of its products expected to be selected in this procurement process [1] Group 1: Procurement Details - The procurement involves products from the first to the eighth batch of national organized procurement agreements that have expired, with the purchasing volume based on the demand reported by medical institutions [1] - The procurement cycle will last until December 31, 2028, starting from the actual implementation date of the selected results [1] Group 2: Financial Impact - The company expects to achieve sales revenue of 176.18 million yuan from the selected products in 2024, accounting for 12.47% of the company's total revenue for that year [1] - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 3: Market Implications - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed purchasing volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and enhance the company's brand influence in the domestic market [1]

Group 1 - The company and its subsidiary, Hubei Tiensheng Pharmaceutical Co., Ltd., participated in the national organized procurement for drugs whose agreements have expired, and some products are proposed to be selected for this procurement [1] - If the procurement contracts are signed and implemented, it will help expand the sales range of the relevant products, increase market share, and enhance brand influence [1] Group 2 - The announcement was made on February 11, 2026, by the board of directors of Tiensheng Pharmaceutical Group Co., Ltd. [2]

Group 1 - The company announced that its subsidiaries participated in a national centralized procurement process, with some products expected to be selected for procurement [1] - The procurement period for the selected products will last until December 31, 2028, and the company is unable to calculate the supply quantity at this time [1] - If the selected products are confirmed and contracts are signed, it will positively impact the company's sales, market share, and brand influence [2] Group 2 - The company approved a share repurchase plan on January 16, 2026, with a maximum repurchase price of 23.98 yuan per share and a minimum repurchase amount of 60 million yuan [6] - As of February 11, 2026, the company has repurchased a total of 6,856,400 shares, representing 0.65% of the total share capital, with a total expenditure of approximately 118.54 million yuan [7] - The repurchase will not significantly affect the company's operations, financial status, or future development, and the share distribution will still meet listing requirements [8]

Core Viewpoint - The company, Bory Pharmaceutical (Suzhou) Co., Ltd., has announced that its subsidiary, Bory Pharmaceutical, is expected to be selected for the national drug procurement program, which could significantly impact its sales and market presence [1][2]. Group 1: Product Selection Details - The company participated in the national drug procurement program for products whose agreements have expired, with the selection results published on February 10, 2026 [1]. - Four products from the company are expected to be selected, which accounted for a total sales revenue of 88.8475 million yuan in the first three quarters of 2025, representing 10.16% of the company's total revenue during that period [2]. Group 2: Impact of Selection - The procurement cycle for the selected products will last until December 31, 2028, with medical institutions prioritizing the use of these selected drugs, which is expected to enhance sales volume and market share [2]. - If contracts are signed and implemented, it will further boost the company's brand image and sales performance [2].

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has participated in the national organized procurement for expiring drug agreements and has several products expected to be selected for continued procurement, which is anticipated to positively impact the company's market share and future operating performance [1][2]. Group 1: Announcement of Selected Products - The company participated in the national organized procurement for expiring drug agreements on February 9, 2026, and has several key products expected to be selected for this procurement [1]. - The selected products include the top five in terms of revenue scale, with additional products such as Venlafaxine Hydrochloride Sustained-Release Capsules also participating [1]. - The procurement cycle for the selected products will run from the date of selection until December 31, 2028 [1]. Group 2: Impact of Selection on the Company - The expected selection of products is projected to stabilize the company's existing market share despite a decrease in sales prices [2]. - The company aims to leverage its brand influence and reliable supply capabilities to further increase its market share, which is expected to have a positive impact on future operating performance [2]. - The implementation of the procurement results is anticipated to begin by the end of March 2026, with provincial medical institutions signing procurement contracts based on the selection results [2].